ArticleBlood cancer journal2016

Crizotinib treatment for refractory pediatric acute myeloid leukemia with RAN-binding protein 2-anaplastic lymphoma kinase fusion gene.

A Hayashi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.